Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurelio Fuertes

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Medicina Clinica|December 4, 2012
[Anticoagulation in polypathological patients with atrial fibrillation]Jesús Díez-Manglano, Máximo Bernabeu-Wittel, Bosco Barón-Franco, et al.
European Journal of Internal Medicine|January 31, 2012
Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patientsJavier Galindo-Ocaña, Máximo Bernabeu-Wittel, Francesc Formiga, et al.
Personalized Medicine|May 17, 2018
Toxicogenetics of lopinavir/ritonavir in HIV-infected European patientsElena López Aspiroz, Salvador Enrique Cabrera Figueroa, Raquel Cruz, et al.
Pharmacogenomics|June 24, 2014
Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogeneticsAlmudena Sánchez Martín, Alicia Iglesias Gómez, Belén García-Berrocal, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Medicina Clinica|December 4, 2012
[Anticoagulation in polypathological patients with atrial fibrillation]Jesús Díez-Manglano, Máximo Bernabeu-Wittel, Bosco Barón-Franco, et al.
European Journal of Internal Medicine|January 31, 2012
Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patientsJavier Galindo-Ocaña, Máximo Bernabeu-Wittel, Francesc Formiga, et al.
Personalized Medicine|May 17, 2018
Toxicogenetics of lopinavir/ritonavir in HIV-infected European patientsElena López Aspiroz, Salvador Enrique Cabrera Figueroa, Raquel Cruz, et al.
Pharmacogenomics|June 24, 2014
Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogeneticsAlmudena Sánchez Martín, Alicia Iglesias Gómez, Belén García-Berrocal, et al.
Pageof 2